Pfizer heads into earnings with a lower Goldman Sachs price target as investors weigh patent risks, Covid declines, and ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while signaling a pivot toward obesity drug programs as well as a larger slate of ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Pfizer shows steady pharmaceutical progress with oncology growth and drug protection strength, shaping healthcare dynamics ...

Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing ...